Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST v1.1-defined disease progression in clinical trials

Based on anecdotal cases of clinically important decreases in tumor size following initial evidence of disease progression when treating patients with anti-PD-1 therapies, investigators have conducted clinical trials in patients with metastatic non-small lung cancer (mNSCLC) receiving anti-PD-1 therapy allowing for treatment past RECIST-defined disease progression (TPP). However, it remains unclear what the true benefit of TPP is.

Source: Seminars in Oncology - February 9, 2017 Category: Cancer & Oncology Authors: Dickran Kazandjian, Patricia Keegan, Daniel L Suzman, Richard Pazdur, Gideon M Blumenthal Source Type: research